Literature DB >> 12708256

[Chronic subdural hematoma: a disease of elderly people].

Patricio Tagle1, Francisco Mery, Gonzalo Torrealba, Sergio Del Villar, Hans Carmona, Manuel Campos, Jorge Méndez, Ada Chicharro.   

Abstract

BACKGROUND: The lack of specificity and heterogeneity of the clinical picture of chronic subdural hematoma, hampers its diagnosis. AIM: To report the experience of a Neurosurgical Service in chronic subdural hematoma. PATIENTS AND METHODS: One hundred patients (77 male, mean age 77 +/- 13 years) with chronic subdural hematoma were analyzed.
RESULTS: The main clinical presentations were mental status changes (50%) and progressive focal neurological deficit (46%). Five cases presented as a transient neurological deficit. All patients were treated with burr hole drainage. Thirteen had recurrence of the hematoma and they were reoperated. The surgical mortality was 3%. Eighty seven patients were followed for a mean of 66 months. Eighty one of these had a complete recovery, 6 had permanent neurological deficit and 2 of these were unable to care for themselves. Bad prognosis was associated with the absence of a previous trauma to explain the hematoma and symptoms of dementia as the clinical presentation.
CONCLUSIONS: Most patients with chronic subdural hematoma treated with burr hole drainage have a good outcome.

Entities:  

Mesh:

Year:  2003        PMID: 12708256

Source DB:  PubMed          Journal:  Rev Med Chil        ISSN: 0034-9887            Impact factor:   0.553


  2 in total

1.  Demographics and prevalent risk factors of chronic subdural haematoma: results of a large single-center cohort study.

Authors:  H Baechli; A Nordmann; H C Bucher; O Gratzl
Journal:  Neurosurg Rev       Date:  2004-05-18       Impact factor: 3.042

2.  Tranexamic acid to prevent operation in chronic subdural haematoma (TORCH): study protocol for a randomised placebo-controlled clinical trial.

Authors:  S Immenga; R Lodewijkx; Y B W E M Roos; S Middeldorp; C B L M Majoie; H C Willems; W P Vandertop; D Verbaan
Journal:  Trials       Date:  2022-01-18       Impact factor: 2.279

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.